IVERIC bio — Ophthotech — 36th Annual J.P. Morgan Healthcare Conference 2018
28 slides from IVERIC bio's conference presentation, Jan 10, 2018

Slide 1: 36th Annual J.P. Morgan Healthcare Conference
1 NASDAQ: OPHT January 2018 36th Annual J.P. Morgan Healthcare Conference Glenn Sblendorio, Chief Executive Officer and President

Slide 2: Forward-looking statements
2 Forward‐looking statements Any statements in this presentation about Ophthotech’s future expectations, plans and prospects constitute forward‐looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward‐looking statements include

Slide 3: Science Driven and Retina Focused
3 Science Driven and Retina Focused • Deep Expertise in Ophthalmic Drug Development - Multiple retina specialists - Strong global KOL network to facilitate clinical execution - Highly experienced clinical development team • Current Clinical Programs - Age‐related Clinical trials in wet and dry AMD

Slide 4: Value Creation: Multiple Track Strategy
4 Value Creation: Multiple Track Strategy Age‐related Diseases Multiple opportunities in large markets where medical need remains for patients Orphan Diseases Focus on underserved patients with the potential for an accelerated path to market Business Development Disciplined approach to evaluation of

Slide 5: Diversified Pipeline in Age-related and Orphan Diseases
5 Diversified Pipeline in Age‐related and Orphan Diseases Zimura® (Complement C5 inhibitor) Autosomal Recessive Stargardt Disease (Orphan) • Phase 2b trial ongoing (monotherapy) • ~ 120 Patients / Primary endpoint at Month 18 • Top‐line data expected in 2020 Wet AMD • Phase 2a trial ongoing (in comb

Slide 6: Multiple Catalysts Near-term and Beyond
6 Multiple Catalysts Near‐term and Beyond Zimura (Complement C5 inhibitor) Wet AMD Complete Enrollment 2018 2019 2020 Wet AMD Phase 2a data Dry AMD (GA) Phase 2b data Stargardt Disease Phase 2b data Top‐line data based on current projections Posterior Uveitis Initiate Phase 2a IPCV Phase 2a data Dia

Slide 7: Zimura, C5 Complement Inhibitor: Geographic Atrophy Secondary to Dry AMD
7 Zimura, C5 Complement Inhibitor Geographic Atrophy Secondary to Dry AMD

Slide 8: Development of Zimura for Geographic Atrophy Secondary to Dry AMD
8 • Major unmet medical need – Large market with no approved treatment options available • Role of complement in dry AMD1 – Complement deposition increases with aging – Complement activation leads to the formation and accumulation of inflammasomes and Membrane Attack Complex (MAC) – Inflammasomes an

Slide 9: Zimura - Complement C5 Inhibitor
9 C3 C3b C5 C4 C2 C3 C3 C3b C3b C4b C4b C3b C5b C5b C 8 C 9 C 9 C6 C7 Pathogen C3bC3b C2a C6‐C9 Factor H C1q C1r C1s CD46 CD46 Microbial Cell Surface Alternative PathwayLectin Pathway Classical Pathway Pathogen Zimura ‐ Complement C5 Inhibitor Inhibition of C5 prevents the formation of C5a and C5b‐9

Slide 10: Zimura Phase 1/2a Dry AMD (GA) – Completed
10 Zimura Phase 1/2a Dry AMD (GA) – Completed* Study Design Intravitreal Zimura was administered for a maximum of 5 injections at one of two dose levels (0.3 mg/eye or 1mg/eye) 47 Patients Enrolled 0.3 mg dose group (n=24) 1 mg dose group (n=23) 0 4 8 12 16 20 24 28 32 36 40 44 48Week Zimura Dosed *

Slide 11: Zimura Phase 1/2a Dry AMD (GA) – Completed
11 Zimura Phase 1/2a Dry AMD (GA) – Completed* • Potential efficacy signal(s) • Presence of a dose‐response trend with “on‐off effect” • Safety • No Zimura related adverse events • Zero incidence of wet AMD in eyes treated with Zimura *Uncontrolled safety trial; small sample size (n=24) (n=23)

Slide 12: Zimura Phase 2b Dry AMD (GA) Clinical Trial – Ongoing
12 Zimura Phase 2b Dry AMD (GA) Clinical Trial – Ongoing • Phase 2b, randomized, double masked, sham controlled clinical trial • Study recently amended to accelerate anticipated timeline to obtain data • ~ 200 subjects will be treated with monthly study treatment (Zimura or Sham) for 18 months • Pri

Slide 13: Zimura, C5 Complement Inhibitor: Wet Age-Related Macular Degeneration
13 Zimura, C5 Complement Inhibitor Wet Age‐Related Macular Degeneration

Slide 14: Unmet Need: Current Standard of Care – Anti-VEGF Monotherapy
14 “The processes responsible for the decrease in vision in CATT and other studies are multiple, but seem to be related to an increase in the proportion patients with an abnormally thin retina (< 120 µm), an increase in prevalence of geographic atrophy, . . . " “These data highlight the need for age

Slide 15: Development of Zimura for Wet AMD
15 • Unmet medical need remains– major market opportunity • Anti‐VEGF monotherapy: – Shown to reach a ceiling effect – Majority of patients do not reach a visual acuity of 20/40 or better – In the real world most patients lose vision over time • Role of Complement in Wet AMD1 – VEGF Increases Comple

Slide 16: Zimura Phase 1/2a Wet AMD – Completed
16 Zimura Phase 1/2a Wet AMD – Completed* 46% 47% 60% 0% 15% 30% 45% 60% 0.3 mg 1.0 mg 2.0 mg n=13 n=15 n=15 ≥ 3‐ETDRS Lines Visual Gain at Week 24 % P a t i e n t s • Included: - Treatment‐naïve patients - All CNV subtypes - Patients receiving six monthly doses of Zimura in combination with Lucenti

Slide 17: Zimura Wet AMD Clinical Trial – Ongoing
17 • Phase 2a open label clinical trial • N = ~ 60 subjects • Objectives: – To assess the safety of intravitreal Zimura administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with wet AMD – Dose ranging – Validate results from previously completed Phase 1/2a • Duration: 6 mont

Slide 18: Zimura, C5 Complement Inhibitor: Autosomal Recessive Stargardt Disease (STGD1)
18 Zimura, C5 Complement Inhibitor Autosomal Recessive Stargardt Disease (STGD1) (Orphan Indication)

Slide 19: Development of Zimura in Autosomal Recessive Stargardt Disease
19 • High unmet medical need – Orphan disease – No FDA or EMA approved treatment available • Role of Complement in Stargardt Disease1 – Bisretinoids (visual cycle waste) activate complement – Complement inhibition rescues photoreceptor cells in a Stargardt animal model – Anti‐C5 improved RPE cell vi

Slide 20: ABCA4 Gene Mutation (Autosomal Recessive Stargardt, STGD1)
20 ABCA4 Gene Mutation (Autosomal Recessive Stargardt, STGD1): Waste Accumulation InflammationX Complement inhibition may potentially lead to healthier RPE cells = Better ability to process and recycle the waste and therefore slow down the progression of Stargardt disease (1) Waste Accumulation Wast

Slide 21: Stargardt Albino Abca4-/- Mice: Complement Inhibition Rescues Photoreceptors
21 Stargardt Albino Abca4‐/‐Mice: Complement Inhibition Rescues Photoreceptors Expression of Complement Inhibitory Protein (CRRY) ~2 fold decrease in bisretinoid accumulation ~30% increase in the number of photoreceptor nuclei Normalized Complement Activity Source: Proc Natl Acad Sci U S A. 2017; 11

Slide 22: Zimura Stargardt Disease (STGD1) Clinical Trial - Initiated
22 • Phase 2b, randomized, double masked, sham controlled clinical trial • N = ~ 120 subjects • Duration of treatment: 18 months • Primary Endpoint: Mean rate of change in the area of ellipsoid zone defect measured by en face SD‐OCT Top‐line data expected in 2020 Zimura Stargardt Disease (STGD1) Cli

Slide 23: OPHT / Foundation Fighting Blindness
23 • OPHT agreement with Foundation Fighting Blindness (FFB) – Highly‐distinguished organization recognized for its scientific commitment to orphan inherited retinal diseases – Established network of scientists and a robust patient registry • Access to FFB’s publicly available ProgStar study – Large

Slide 24: Pipeline Expansion Strategy
24 Become a leader in the development of novel therapeutics for age‐related and orphan diseases of the eye Orphan & Retina Indications (opportunistic in other ocular) Seek Ophthalmology Assets in Preclinical/Development • Previously evaluated 125+ ophthalmology assets • Seeking additional assets in

Slide 25: Financial Highlights: Strong Cash Position
25 Financial Highlights • ~$167 million in cash and cash equivalents as of 12/31/171 • External costs to bring Zimura programs to next phase of development expected to range between $25 million and $35 million2 • Cash corporate overhead expenses expected to average less than $2 million per month and

Slide 26: Executing on Strategic Plan: Age-related and Orphan Ophthalmic Indications
26 Zimura Wet AMD Phase 2a ongoing Dry AMD Phase 2b ongoing Stargardt Disease Phase 2b ongoing IPCV Phase 2a ongoing Posterior Uveitis Phase 2a to initiate in 2018 Business Development Orphan ophthalmic and retinal diseases with therapeutic and/or gene therapy solutions Executing on St

Slide 27: Multiple Catalysts Near-term and Beyond
27 Multiple Catalysts Near‐term and Beyond Zimura (Complement C5 inhibitor) Wet AMD Complete Enrollment 2018 2019 2020 Wet AMD Phase 2a data Dry AMD (GA) Phase 2b data Stargardt Disease Phase 2b data Top‐line data based on current projections Posterior Uveitis Initiate Phase 2a IPCV Phase 2a data Di

Slide 28: 36th Annual J.P. Morgan Healthcare Conference
28 NASDAQ: OPHT January 2018 36th Annual J.P. Morgan Healthcare Conference Glenn Sblendorio, Chief Executive Officer and President
Source: SEC EDGAR · 8-K filed Jan 10, 2018



